Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Dose Escalation and Dose Expansion Study of WJ01024 to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy for Patients With Advanced Cancer

NCT04991129 is registered in ClinicalTrials.gov with Suzhou Junjing BioSciences Co., Ltd. as lead sponsor.

NCT NCT04991129
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04991129 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Dose Escalation and Dose Expansion Study of WJ01024 to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy for Patients With Advanced Cancer
Lead sponsor
Suzhou Junjing BioSciences Co., Ltd.
Phase
Phase 1
Overall status
Terminated
Start date
September 10, 2021
Completion date
May 28, 2025
Enrollment
23 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

advanced hematologic malignancies, advanced solid tumors